• Capecitabine in Preclinical Oncology: Workflow, Tips & Insig

  2026-07-29

  Leverage Capecitabine’s tumor-selective activation for advanced assembloid and organoid cancer models. This guide delivers actionable workflows, protocol benchmarks, and troubleshooting strategies, bridging the latest evidence from patient-derived assembloid research to practical experimental design.

• Enantiomeric Polymer Effects on IR-1061 Encapsulation for NI

  2026-07-28

  This study investigates how the chiral structure of hydrophobic poly(lactic acid) polymers influences the encapsulation and fluorescence properties of IR-1061, a near infrared fluorescent dye, for deep in vivo imaging. The findings provide mechanistic insights for optimizing dye–polymer pairings in advanced biomedical imaging probes.

• AG-120 (Ivosidenib): Redefining IDH1 Mutant Cancer Therapy

  2026-07-28

  Explore how AG-120 (Ivosidenib) targets mutant IDH1 to reduce 2-hydroxyglutarate, restore myeloid differentiation, and address key resistance mechanisms in AML. Uncover unique insights into metabolic vulnerabilities and advanced research applications.

• CD44-Driven Metabolic Rewiring in IDH-Mutant AML: Therapeuti

  2026-07-27

  This study uncovers how CD44 upregulation underpins metabolic adaptation in IDH-mutant acute myeloid leukemia (AML) by sustaining NADPH generation and oncometabolite 2-hydroxyglutarate (2-HG) production. The findings highlight the therapeutic potential of targeting the CD44-metabolic axis, particularly in combination with mutant IDH1 inhibition, to overcome resistance and improve outcomes in AML.

• CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Ce

  2026-07-27

  The CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Cell Tracer Kit offers stable, long-term fluorescent labeling for cell proliferation and lineage tracing in both in vitro and in vivo workflows. It is not intended for reversible, short-term, or non-covalent cell labeling protocols. Researchers requiring persistent, minimally cytotoxic cell tracing will find this kit suitable for tracking cell fate and proliferation.

• ddhCTP (3ʹ-deoxy-3′,4ʹ-didehydro-CTP): Mechanism and Antivir

  2026-07-26

  ddhCTP (3ʹ-deoxy-3′,4ʹ-didehydro-CTP) is a biologically derived nucleotide analog that acts as a potent inhibitor of RNA virus replication. Its antiviral effect is mediated by chain termination of viral RNA synthesis, particularly in flaviviruses, and is generated through the action of the interferon-stimulated enzyme viperin. This article critically examines ddhCTP's mechanism, supporting evidence, and integration into antiviral workflows.

• Predicting Major Bleeding in Extended Anticoagulation for VT

  2026-07-25

  This study introduces and validates the CHAP model, a simplified yet effective tool for predicting major bleeding during extended anticoagulation in patients with unprovoked or weakly provoked venous thromboembolism (VTE). By comparing CHAP with established risk scores, the research clarifies risk stratification, offering practical implications for optimizing patient safety.

• Cyclosporin A: Advancing Immunosuppression and Mitochondrial

  2026-07-24

  Explore the molecular mechanisms and advanced research applications of Cyclosporin A in immunosuppression and cell survival. This article provides new insights into apoptosis modulation and mitochondrial regulation, distinguishing itself from standard protocol-focused content.

• Sulfo-Cy5 NHS Ester (SKU A8108): Reliable Protein Labeling f

  2026-07-24

  Sulfo-Cy5 NHS ester (SKU A8108) delivers reproducible, hydrophilic fluorescent labeling for sensitive protein and cell-based assays. This article explores practical scenarios, protocol parameters, and benchmarking guidance for biomedical researchers seeking robust, low-quenching solutions for protein conjugation and advanced cellular imaging.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ): Engineering Resilient Cytoki

  2026-07-23

  Discover how EZ Cap™ Mouse IL-12 mRNA (m1Ψ) empowers advanced immunotherapy research by enabling robust, stable cytokine expression with minimal innate immune activation. This article offers a deep dive into delivery mechanics, translational limitations, and new frontiers in immune modulation.

• AZD8055: Technical Parameters for mTOR Inhibition in Researc

  2026-07-23

  AZD8055 is a potent, selective ATP-competitive mTOR inhibitor designed for robust inhibition of both mTORC1 and mTORC2 in preclinical research. It is best suited for mechanistic studies of mTOR signaling and cancer cell proliferation in cell-based and animal models, but is not recommended where clinical efficacy or water solubility is required.

• BCECF for Translational Research: Precision pH Sensing Reima

  2026-07-22

  Explore how BCECF (2',7'-bis(carboxyethyl)-5(6)-Carboxyfluorescein) empowers translational researchers to dissect extracellular pH dynamics in complex disease models. By integrating mechanistic insights from neuropathic pain research, benchmarking performance, and delivering actionable protocol guidance, this article provides a unique, strategic roadmap for leveraging advanced pH measurement tools in preclinical and translational workflows. Discover how APExBIO’s BCECF stands apart from standard solutions and what the future holds for precision pH sensing.

• Iptacopan (LNP023): Translating Factor B Inhibition Into Cli

  2026-07-22

  Explore the unique pharmacological and translational profile of Iptacopan (LNP023), a selective oral complement factor B inhibitor. This article delivers a deep dive into its mechanism, therapeutic potential, and clinical evidence—offering practical insights beyond protocol guides.

• EV-Transferred ACLY Drives Macrophage Immunosuppression in H

  2026-07-21

  This study reveals that hepatocellular carcinoma (HCC) cells secrete extracellular vesicles (EVs) containing ATP-citrate lyase (ACLY), which are taken up by monocytes and induce their differentiation into immunosuppressive tumor-associated macrophages (TAMs). The findings elucidate a metabolic pathway for TAM formation in the tumor microenvironment and highlight ACLY as a promising therapeutic target to enhance immunotherapy efficacy in HCC.

• Inducing Bleb Structures in LNP-mRNA Boosts Transfection Pot

  2026-07-21

  A recent study demonstrates that formulating lipid nanoparticle (LNP) mRNA systems to induce mRNA-rich bleb structures—specifically by using high-concentration pH 4 sodium citrate buffers—substantially enhances transfection efficiency in vitro and in vivo. This finding highlights the importance of formulation parameters in optimizing mRNA delivery, with implications for both therapeutic development and experimental gene expression assays.

15901 records 1/1061 page Next 12345 下5页 Last page